Correlation Between Garuda Construction and Biofil Chemicals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Garuda Construction and Biofil Chemicals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Garuda Construction and Biofil Chemicals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Garuda Construction Engineering and Biofil Chemicals Pharmaceuticals, you can compare the effects of market volatilities on Garuda Construction and Biofil Chemicals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Garuda Construction with a short position of Biofil Chemicals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Garuda Construction and Biofil Chemicals.

Diversification Opportunities for Garuda Construction and Biofil Chemicals

0.25
  Correlation Coefficient

Modest diversification

The 3 months correlation between Garuda and Biofil is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Garuda Construction Engineerin and Biofil Chemicals Pharmaceutica in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biofil Chemicals Pha and Garuda Construction is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Garuda Construction Engineering are associated (or correlated) with Biofil Chemicals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biofil Chemicals Pha has no effect on the direction of Garuda Construction i.e., Garuda Construction and Biofil Chemicals go up and down completely randomly.

Pair Corralation between Garuda Construction and Biofil Chemicals

Assuming the 90 days trading horizon Garuda Construction Engineering is expected to generate 2.49 times more return on investment than Biofil Chemicals. However, Garuda Construction is 2.49 times more volatile than Biofil Chemicals Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Biofil Chemicals Pharmaceuticals is currently generating about -0.23 per unit of risk. If you would invest  8,979  in Garuda Construction Engineering on September 1, 2024 and sell it today you would lose (32.00) from holding Garuda Construction Engineering or give up 0.36% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Garuda Construction Engineerin  vs.  Biofil Chemicals Pharmaceutica

 Performance 
       Timeline  
Garuda Construction 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Garuda Construction Engineering has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Biofil Chemicals Pha 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Biofil Chemicals Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound technical indicators, Biofil Chemicals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Garuda Construction and Biofil Chemicals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Garuda Construction and Biofil Chemicals

The main advantage of trading using opposite Garuda Construction and Biofil Chemicals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Garuda Construction position performs unexpectedly, Biofil Chemicals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biofil Chemicals will offset losses from the drop in Biofil Chemicals' long position.
The idea behind Garuda Construction Engineering and Biofil Chemicals Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum